For a list of publications please click here (Pubmed) or here (Google Scholar). 

Highlighted Research Publications

• B. Lin/ Y. Li / A. Goula, … & D. Van der Meer / J.J. Luykx. Dissecting causal relationships between cortical morphology and neuropsychiatric disorders: a bidirectional Mendelian randomization study (Nature Mental Health, in press): using large genetic data we show that cortical thinning is a risk factor for schizophrenia and not vice versa. 

• N.Joore, … & J.J. Luykx. Positive Associationbetween Mean Ambient Temperature and Involuntary Admissions to PsychiatricFacilities (European Psychiatry, 2025). 

• J.J. Luykx / R. Visscher, … & A. Hasan / B. Lennox. Clinical symptoms and psychosocial functioning in patients with schizophrenia spectrum disorders testing seropositive for NMDAR antibodies: case-control comparison with patients testing negative (The Lancet Psychiatry, 2024): we collected the largest cohort of schizophrenia patients with anti-NMDAR serostatus and clinical symptoms, and show that those testing positive have less negative symptoms and function better, with no differences in positive symptoms between seropositive and seronegative patients. 

• J.J. Luykx, … & H. Taipale. Incident pneumonia in patients with schizophrenia: associations with antipsychotic dose and anticholinergic burden (JAMA Psychiatry, 2024): we show how an important cause of death in schizophrenia, pneumonia, is associated with antipsychotic dosing and anticholinergic burden, not with clozapine specifically.  

• O. Efthimiou / H. Taipale / J. Radua / J. Schneider-Thoma / J. Pinzón-Espinosa / M. Ortuño, …, & J.J. Luykx. Efficacy and Effectiveness of Antipsychotics in Schizophrenia: Combining Evidence from Randomised Controlled Trials and Real-World Data (The Lancet Psychiatry, 2024): we found a way to combine RCT and real-world data on the efficacy and effectiveness of antipsychotics and then ran joint analyses, revealing insights into how RCT-findings generalize to real-world settings, e.g. we find that relative effects of antipsychotics largely agree between the two settings but that long-acting injectables are more effective relative to their oral counterparts only in the real-world. 

• B. Lin / J. Pinzón-Espinosa, ..., & J.J. Luykx. Associations between polygenic loading, psychosis liability and clozapine us (JAMA Psychiatry, 2023): leveraging rich phenotypic and genotypic data from several cohorts we demonstrate how polygenic risk scores vary according to a psychosis liability spectrum and may be predictive of future clozapine use.

• B. Lin, …, & J.J. Luykx. Associations between genetic liabilities to smoking behavior andschizophrenia symptoms in patients with a psychotic disorder, their siblingsand healthy controls (Psychiatry Research, 2023): we show howsmoking behavior polygenic liabilities differentially associate with symptomlevels across patients, siblings and healthy controls.

• H. Taipale / J. Thoma-Schneider / J. Pinzón-Espinosa, …, & J.J. Luykx. Representation and Outcomes of Individuals With Schizophrenia Seen in Everyday Practice Who Are Ineligible for Randomized Clinical Trials (JAMA Psychiatry, 2022): we found a way to analyze real-world representation of schizophrenia patients eligible for RCTs, which turned out to be only around 20%, leading us to call for more inclusive RCTs.

• J.J. Luykx / D. Loef / B. Lin, …& A. Dols / B. Rutten. Interrogating Associations between Polygenic Liabilities and Electroconvulsive Therapy Effectiveness (Biological Psychiatry, 2022): I united collaborators over Europe to collect the largest ECT responsiveness dataset with DNA to date and found a strong and linear, consistent association between PRS-schizophrenia and ECT responsiveness. 

• Okhuijsen-Pfeifer / M. van der Horst / B. Lin / C. Bousman, …. & J.J. Luykx. Genome-wide association analyses of symptom severity among clozapine-treated patients with schizophrenia spectrum disorder (Translational Psychiatry, 2022): using data collected in a large consortium led by myself, CLOZIN, we demonstrate that high polygenic risk scores for schizophrenia are associated with lower burden of symptoms in patients with schizophrenia who are using clozapine. 

• M. Olislagers, K. Rademakers, R. Adan, B. Lin & J.J. Luykx. Comprehensive analyses of RNA-seq and genome-wide data point to enrichment of neuronal cell type subsets in neuropsychiatric disorders (Molecular Psychiatry, 2022): using available genetic data of millions of people we show that neuronal subsets are consistently implicated in psychiatric disorders while in neurological disorders a variety of CNS cells are involved.

• N. de Boer, …& J.J. Luykx. Longitudinal associations between alcohol use, smoking, genetic risk scoring, and symptoms of depression in the general population: a prospective six-year cohort study (Psychological Medicine, 2021): with collaborators from TRIMBOS in a longitudinal cohort with phenotypic and genotype data we show that reducing smoking and alcohol use diminishes depressive symptoms later on.

• J.J. Luykx & B. Lin. Are psychiatric disorders risk factors for COVID-19 susceptibility and severity? a two-sample, bidirectional, univariable and multivariable Mendelian Randomization study (Translational Psychiatry, 2021): using large genetic datasets we show it’s unlikely that psychiatric disorders increase COVID-19 risk. 

• J.J. Luykx, N. Stam, …. & Heidi Taipale. In the aftermath of clozapine discontinuation: comparative effectiveness and safety of antipsychotics in patients stopping clozapine (British Journal of Psychiatry, 2020): with Finnish collaborators we show that in those stopping clozapine for unknown reasons restarting clozapine and olanzapine are safest and most effective. 

• B.D. Lin, A. Alkema, …. & J.J. Luykx. Assessing causal links between metabolic traits, inflammation and schizophrenia: a univariable and multivariable bidirectional Mendelian Randomization study (International Journal of Epidemiology, 2019): using both univariate and multivariate MR we find evidence that dyslipidemia has a role in schizophrenia independent of medication status. 

• R. McLaughlin, D. Schijven,….. & O. Hardiman / J.H. Veldink / J.J. Luykx. Genetic correlation between amyotrophic lateral sclerosis and schizophrenia (Nature Communications, 2017): in an international consortium set up by others and myself we found the first evidence of genetic overlap between schizophrenia and ALS.  

Highlighted Collaborative Work

• K. O’Connell, …, J.J. Luykx, et al. Genomics yields biological and phenotypic insights into bipolar disorder (Nature, in press).
• M. Adams, …., J.J. Luykx, et al. Genome-wide study of half a million individuals with major depression identifies 697 independent associations, infers causal neuronal subtypes and biological targets for novel pharmacotherapies (Cell, in press).
• N. Strom, …, J.J. Luykx, et al. Genome-wide association study identifies 30 obsessive-compulsive disorder associated loci (Nature Genetics, in press).
• N. Daskalakis, … J.J. Luykx, et al. Systems biology dissection of PTSD and MDD across brain regions, cell types, and blood (Science, 2024).
• C. Nivergelt, …, J.J. Luykx, et al. Discovery of 95 PTSD loci provides insight into genetic architecture and neurobiology of trauma and stress-related disorders (Nature Genetics, 2024).
• I. Winter, …, J.J. Luykx, et al. Effectiveness of oral versus long-acting antipsychotic treatment in early-phase schizophrenia patients: a large-scale, open-label, randomized trial (EULAST; Lancet Psychiatry, 2023).
• A. Higgins, …, J.J. Luykx, et al. A computational solution for bolstering reliability of epigenetic clocks: Implications for clinical trials and longitudinal tracking (Nature Aging, 2022).
• B. Lin, …. J.J. Luykx & S. Guloksuz. Nongenetic Factors Associated With Psychotic Experiences Among UK Biobank Participants: Exposome-Wide Analysis and Mendelian Randomization Analysis (JAMA Psychiatry, 2022).
• V. Trubetskoy, …, J.J. Luykx, et al. Mapping genomic loci prioritises genes and implicates synaptic biology in schizophrenia (Nature, 2022).
• K. Gatsby, …., J.J. Luykx, et al. The Genetic Architecture of the Human Cerebral Cortex (Science, 2020).
• L. Katrin-Pries, …, J.J. Luykx, B. Rutten & S. Guloksuz. The main and interacting effects of recent stressful life events with genomic and exposomic liability for schizophrenia on mental and physical health (JAMA Psychiatry, 2020).
• S. Guloksuz, …, J.J. Luykx, B. Rutten & J. van Os. Association of preceding psychosis risk states and non-psychotic mental disorders with incidence of clinical psychosis in the general population: a prospective study in the NEMESIS-2 cohort (World Psychiatry, 2020).
• Cross-disorder group of the psychiatric genomics consortium, …., J.J. Luykx, et al. Genome-wide meta-analysis identifies genomic relationships, novel loci, and pleiotropic mechanisms across eight psychiatric disorders (Cell, 2019).
• L. Duncan, …., J.J. Luykx, et al. Anorexia nervosa genome-wide association study identifies eight loci implicating metabo-psychiatric origins (Nature Genetics, 2019). 

Highlighted Review Papers

• J.J. Luykx, … & C.H. Vinkers. Environmentally conscious psychopharmacotherapy: Practice recommendations for psychiatrists (Eur. Neuropsychopharmacology, 2024).
• C.H. Vinkers, …, & J.J. Luykx. Discontinuation of psychotropic medication: a synthesis of evidence across medication classes (Molecular Psychiatry, 2024): for the most commonly prescribed psychotropic medications we summarize the current evidence on the safety of discontinuation and ways to improve this safety.
• J.J. Luykx / J. Gonzalez, …, & J. Tiihonen. An international research agenda for clozapine-resistant schizophrenia (Lancet Psychiatry, 2023): with a group of experts, such as clinician-scientists, experienced experts, and family members from across the globe we highlight unmet needs in the treatment of difficult-to-treat psychosis and propose an international research agenda to improve outcomes of people with such conditions.
• J. Pinzón-Espinosa / M. van der Horst, …., & J.J. Luykx. Barriers to genetic testing in clinical psychiatry and ways to overcome them: from clinicians’ attitudes to sociocultural differences between patients across the globe (Translational Psychiatry, 2022): we discuss barriers to genetic testing and ways to overcome them to ensure patients may receive genetic testing in psychiatry when needed.
• E. Eeltink, …, & J.J. Luykx. Polygenic risk scores for genetic counseling in psychiatry: lessons learned from other fields of medicine (Neuroscience & Biobehavioral Reviews, 2021): in this systematic review we show how clinical psychiatry may benefit from applying polygenic scoring to certain diagnostic and therapeutic dilemmas and how the field of psychiatry may learn from experiences in other fields, such as Alzheimer’s dementia.
• C. Okhuijsen-Pfeifer, …, & J.J. Luykx. Demographic and clinical features as predictors of clozapine response in patients with schizophrenia spectrum disorders: a systematic review and meta-analysis (Neuroscience & Biobehavioral Reviews, 2020).
• D. Schijven, J.H. Veldink & J.J. Luykx. Genetic cross-disorder analysis in psychiatry: from methodology to clinical utility (British Journal of Psychiatry, 2020): in this paper we discuss the ramifications and clinical implications of genetic cross-disorder research for patients and psychiatrists. 

Highlighted opinion pieces, editorials and viewpoints

• O. Corbeil, J. Labad, I. Montalvo & J.J. Luykx. Real-world studies in psychiatry: insights into antipsychotic-associated breast cancer risk and broader implications (Br. J. of Psychiatry, in press).
• J.J. Luykx, J. Tiihonen & H. Taipale. Antipsychotic Monotherapy vs Polytherapy for Pneumonia Risk-Reply (JAMA Psychiatry, 2024)
• L. Brandt, …, & J.J. Luykx. Climate Change and Mental Health: Position Paper of the European Psychiatric Association (European Psychiatry, 2024).
• J.J. Luykx & Helena Voetterl. Towards ecologically sustainable mental healthcare: a call for action from within psychiatry (JAMA Psychiatry, 2022).
• J.J. Luykx. Psychiatric organizations should unite voices in condemning the invasion of Ukraine (Lancet Psychiatry, 2022).
• J.J. Luykx & Jari Tiihonen. Antipsychotic discontinuation: mind the patient and the real-world evidence (Lancet Psychiatry, 2021).
• J.J. Luykx, C.H. Vinkers & J.K. Tijdink. Psychiatry in times of the COVID-19 pandemic: an imperative for psychiatrists to act now (JAMA Psychiatry, 2020).
• J.J. Luykx, … & C.H. Vinkers. Safe and informed prescribing of psychotropic medication during the COVID-19 pandemic (British Journal of Psychiatry, 2020).
• J.J. Luykx, A. Di Florio & Veerle Bergink. Prevention of infanticide and suicide in the postpartum period: the importance of emergency care (JAMA Psychiatry, 2019).
• J.J. Luykx, R. van der Spek, …., Annelien Bredenoord & Ger Palmboom. Unconsented genetic testing in psychiatry: an (almost) no go? (Lancet Psychiatry, 2019).
• B. Lin, Y. Li & J.J. Luykx. Mendelian Randomization concerns (JAMA Psychiatry, 2018). 

Books & Smartphone Applications

• ‘Green Planet, Green Care’ (book written with others about how to make healthcare more sustainable; 2024).
• ‘Leerboek Psychiatrie’, chapter ‘Emergency Psychiatry’ (2024).
• ‘Leerboek Interne Geneeskunde’, chapter ‘Psychiatry’ (2024).
• ‘Acute psychiatrie’ (national emergency psychiatry guidelines, director and first author: printed book & website, Van Zuiden communications, 2017 & updated in 2022, BSL by Springer Nature)
• Moleman Psychopharmacology, chapter ‘Antipsychotics’ (2022).
• ‘Leerboek Bipolaire Stoornissen’, chapter ‘Genetics’ (2022).
• ‘Handboek schizofreniespectrumstoornissen’, Chapter ‘Somatic causes of psychosis’ (2019).
• ‘Leerboek acute geneeskunde’ (editor for all chapters on psychiatric disorders and author of some of those chapters, 2018)
• Smartphone application ‘Acute psychiatrie’: easy-to-use application allowing rapid decision-making in emergency psychiatry situations (2018). 

Platforms & Projects
• www.dejongepsychiater.nl: contemporary topics in psychiatry, ranging from new research findings to societal debates and arts.
• Neurologisch onderzoek voor de psychiater (met Klaas Arts, free videos about the essentials of neurological examinations in psychiatry).
• www.psychx.nl: monthly online, free PsychX talks by psychiatrists and researchers working in mental healthcare, set up by Christiaan Vinkers and me
• www.circularpsychiatry.com (under construction): platform to boost eco-friendly and circular mental healthcare.

Selection of media appearances / interviews
• Generative AI for learning in psychiatry, Trouw (2023).
• Psychotropics in surface water, NOS nieuws, Radio 1, Trouw, BNR nieuwsradio & Vroege Vogels, among other outlets (2023).
• Leveraging genetics for improved treatment outcomes in psychiatry, BNR Nieuwsradio (2022).
• Representation and outcomes of patients with psychotic disorders in Volkskrant, Trouw, het AD, DOQ en persbericht van de Universiteit Maastricht (2022).
• Medisch Contact: Extreem rechtse psychose of ideologie? (2020).
• VPRO Tegenlicht Meet-up: Mijn DNA (vanaf minuut 9 beginnend) (2020).
• Medisch Contact: Interview about genetic findings in anorexia nervosa (2019).
• UMC Utrecht: Interview about my research directions (2018).